All Stories

Sanofi pays $600M upfront for Dren Bio's bispecific in latest immunology play

The CD20-directed antibody, dubbed DR-0201, is a bispecific myeloid cell engager that Dren has been testing in a phase 1 trial for B-cell non-Hodgkin lymphoma.

Mar 20, 2025 - 11:51
 0
Sanofi pays $600M upfront for Dren Bio's bispecific in latest immunology play
The CD20-directed antibody, dubbed DR-0201, is a bispecific myeloid cell engager that Dren has been testing in a phase 1 trial for B-cell non-Hodgkin lymphoma.
Read More

Tags:

Previous Article

Third of drivers unaware they could be due compensation in commissions probe

Next Article

Just Drinks Excellence Awards 2025: De Kuyper Royal Distillers

Related Posts

Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects

Biogen axes asset from $7.3B buyout, along with Alzheim...

Feb 12, 2025  0

Flagship's Empress lays off 53% of staffers in push to get science to clinic

Flagship's Empress lays off 53% of staffers in push to ...

Mar 18, 2025  0

Fierce Biotech Fundraising Tracker '25: Newleos emerges with $93M; Abcuro raises $200M

Fierce Biotech Fundraising Tracker '25: Newleos emerges...

Feb 13, 2025  0